Arcadia Biosciences Inc (RKDA) — Cash Flow-to-Debt Ratio
Arcadia Biosciences Inc (RKDA) has a Cash Flow-to-Debt Ratio of -0.36x as of December 2025, meaning its operating cash flow of $-861.00K could theoretically repay 0% of its total liabilities ($2.41 Million) in one year. See Arcadia Biosciences Inc (RKDA) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Arcadia Biosciences Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Arcadia Biosciences Inc across 14 annual periods. Also explore Arcadia Biosciences Inc annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Arcadia Biosciences Inc (2012–2025)
Year-by-year debt coverage analysis for Arcadia Biosciences Inc. For market capitalisation and broader financial context, see Arcadia Biosciences Inc (RKDA) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.97x | $-4.74 Million | $2.41 Million | ▼ -49.2% |
| 2024 | -1.32x | $-9.63 Million | $7.29 Million | ▲ +39.6% |
| 2023 | -2.18x | $-15.29 Million | $7.00 Million | ▼ -25.4% |
| 2022 | -1.74x | $-13.98 Million | $8.02 Million | ▲ +14.3% |
| 2021 | -2.03x | $-25.87 Million | $12.72 Million | ▼ -26.5% |
| 2020 | -1.61x | $-30.22 Million | $18.80 Million | ▼ -126.7% |
| 2019 | -0.71x | $-17.20 Million | $24.25 Million | ▲ +41.7% |
| 2018 | -1.22x | $-13.63 Million | $11.21 Million | ▲ +25.4% |
| 2017 | -1.63x | $-13.96 Million | $8.56 Million | ▼ -228.7% |
| 2016 | -0.50x | $-17.05 Million | $34.38 Million | ▼ -11.7% |
| 2015 | -0.44x | $-15.11 Million | $34.02 Million | ▲ +19.6% |
| 2014 | -0.55x | $-14.79 Million | $26.77 Million | ▼ -52.1% |
| 2013 | -0.36x | $-9.74 Million | $26.84 Million | ▲ +27.9% |
| 2012 | -0.50x | $-9.59 Million | $19.04 Million | — |